Checkpoint Therapeutics Beats Investor Suit Over FDA Assent (1)

Checkpoint Therapeutics Inc. defeated investor claims it concealed the likelihood US regulators would deny its skin cancer treatment’s application due to its manufacturer’s compliance problems, a federal judge ruled.

Most of the purportedly misleading statements about the Food and Drug Administration’s approval process for its therapy cosibelimab were unactionable puffery, opinion, or forward-looking projections, Judge Paul A. Engelmayer said as he tossed the investor’s proposed class allegations with finality Monday. The US District Court for the Southern District of New York added that the investors failed to adequately allege the level of intent or reckless disregard to deceive by Checkpoint ...